Filter by: All20242023202220212020201920182017January 5, 2024 Axial Therapeutics to Present at Upcoming ConferencesPress Release September 26, 2023 Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with AutismPress Release June 20, 2023 Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s DiseasePress Release April 4, 2023 Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)Press Release March 29, 2023 Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome TherapeuticsPress Release November 1, 2022 Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022Press Release October 11, 2022 Axial Therapeutics Expands Clinical Development Capabilities with Key AppointmentsPress Release October 6, 2022 Axial Therapeutics to Present at BioJapan ConferencePress Release September 13, 2022 Axial Therapeutics CEO, A. Stewart Campbell, to Participate at the Longwood Healthcare Leaders Fall WebconferencePress Release July 13, 2022 Seed Health Launches Gut-Brain Development Program with Axial Therapeutics To Translate Caltech Research into Probiotic Innovations for Neuropsychiatric HealthPress Release May 2, 2022 Axial Therapeutics Announces Participation of its CEO, A. Stewart Campbell, in Longwood Healthcare Leaders Spring MIT WebconferencePress Release April 5, 2022 Axial Therapeutics’ Scientific Founder Sarkis Mazmanian, Ph.D., to Present Research Highlighting the Gut-Brain Connection in Autism Spectrum Disorder (ASD) at TACA’s Autism Action ConferencePress Release February 14, 2022 Nature Medicine Publishes Full Results from Axial Therapeutics’ Phase 1b/2a Clinical Trial in Autism Spectrum Disorder (ASD)Press Release February 14, 2022 New Preclinical Research Published in Nature Highlights an Active Role by Microbiome-Derived Metabolites in Brain Function and Anxiety-like BehaviorPress Release November 30, 2021 Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)Press Release October 27, 2021 Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum DisorderPress Release October 13, 2021 Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and DisordersPress Release April 15, 2021 Axial Therapeutics to Present at Virtual Jefferies Microbiome-based Therapeutics SummitPress Release March 8, 2021 Axial Therapeutics Promotes A. Stewart Campbell to Chief Executive OfficerPress Release January 6, 2021 Axial Therapeutics to Present at the Inaugural Virtual H.C. Wainwright BioConnect ConferencePress Release January 6, 2021 Axial Therapeutics to Present at the 2020 RBC Capital Markets Healthcare Private Company ConferencePress Release December 30, 2020 Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021Press Release December 3, 2020 Results from Axial Therapeutics Phase1b/2a Study of AB-2004 in Adolescents with Autism Spectrum Disorder Met Primary Endpoint and Reduced Irritability and Other SymptomsPress Release November 25, 2020 Axial Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare ConferencePress Release November 16, 2020 Axial Therapeutics to Participate in a Fireside Chat Hosted by LifeSci CapitalPress Release September 22, 2020 Axial Biotherapeutics Appoints Federico Bolognani, M.D., Ph.D., Vice President and Head of Clinical SciencePress Release September 15, 2020 Axial Biotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment ConferencePress Release August 12, 2020 Axial Biotherapeutics to Present at The JMP Securities CNS ForumPress Release July 28, 2020 Axial Biotherapeutics Announces a Research Grant Award from The Michael J. Fox Foundation for the Development of an Enteric Nervous System Model to Assess Novel Parkinson’s Disease TherapeuticsPress Release May 27, 2020 Axial Biotherapeutics to Present at the Jefferies Virtual Global Healthcare ConferencePress Release May 22, 2020 Axial Biotherapeutics to Present Virtual Presentation at American Society of Clinical Psychopharmacology (ASCP) 2020 Annual MeetingPress Release April 2, 2020 Axial Biotherapeutics Announces Positive Topline Results from Phase 1b/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum DisorderPress Release March 10, 2020 Axial Biotherapeutics to Present at the Chardan 2nd Annual Microbiome Medicines Virtual SummitPress Release February 12, 2020 Axial Biotherapeutics Strengthens and Expands Board of Directors and Leadership TeamPress Release February 5, 2020 Axial Biotherapeutics to Present at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders’ Emerging Management Therapies for Childhood Neurodevelopmental Disorders Scientific SymposiumPress Release November 26, 2019 Axial Biotherapeutics to Present at the 31st Annual Piper Jaffray Healthcare ConferencePress Release November 18, 2019 Axial Biotherapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial Evaluating AB-2004 in Patients with Autism Spectrum DisorderPress Release October 18, 2019 Axial Biotherapeutics Presents Preclinical Data on Microbiome – Derived Metabolites Associated with Autism Spectrum Disorder at the Society for Neuroscience 2019 Annual MeetingPress Release October 11, 2019 Axial Biotherapeutics to Participate in 5th Annual BMO Private Company ShowcasePress Release July 16, 2019 Axial Biotherapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum DisorderPress Release June 20, 2019 Axial Biotherapeutics Announces $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain AxisPress Release May 31, 2019 Axial Biotherapeutics Announces Publication of Preclinical Data Highlighting the Link Between Human Gut Microbiota and Behavioral Symptoms of Autism Spectrum Disorder in Mouse ModelsPress Release May 28, 2019 Axial Biotherapeutics to Participate in Upcoming Conferences in JunePress Release May 2, 2019 Axial Biotherapeutics Presents New Preclinical Data from AB-2004 Program Demonstrating Reduction of Microbiome-Derived Metabolites in Mouse Models with Autism Spectrum Disorder at the International Society for Autism Research (INSAR) 2019 Annual MeetingPress Release February 27, 2019 Axial Biotherapeutics Raises $25 Million in Series B FinancingPress Release October 30, 2018 Axial Biotherapeutics Strengthens Senior Management Team with Appointment of Jeff Young as Chief Financial OfficerPress Release June 18, 2018 Parkinson’s Institute and Clinical Center and Axial Biotherapeutics Announce Collaboration to Target Gastrointestinal Metabolites that May Contribute to Parkinson’s DiseasePress Release June 12, 2018 Axial Biotherapeutics Announces Neurology Scientific and Clinical Advisory BoardPress Release May 9, 2018 Axial Biotherapeutics Reports Findings of Elevated 4-Ethylphenylsulfate (4-EPS) in Replicate Analyses of Serum Samples from Children with Autism Spectrum Disorder (ASD)Press Release November 2, 2017 Axial Biotherapeutics Strengthens Regulatory Team with Appointment of Dr. Gregory Bates as Senior Vice President of Regulatory AffairsPress Release September 26, 2017 Axial Biotherapeutics Named a “Fierce 15” Biotech Company of 2017 by FierceBiotechPress Release August 22, 2017 Axial Biotherapeutics Announces Appointment of Srinivas G. Rao, M.D., Ph.D., as Chief Medical OfficerPress Release July 12, 2017 Axial Biotherapeutics Makes Inaugural Appointments to its Scientific and Clinical Advisory BoardPress Release June 27, 2017 Axial Biotherapeutics to Host Workshop Highlighting Advances in Gut Microbiome-Brain ConnectionsPress Release April 26, 2017 Axial Biotherapeutics Expands Board of Directors with Appointments of Independent Members Ronald C. Renaud Jr. and Henry C. (“Hank”) WolfPress Release February 3, 2017 Axial Biotherapeutics Co-founder Sarkis Mazmanian to Give Keynote Speech at the Microbiome in Health and Disease Keystone SymposiumPress Release January 19, 2017 Axial Biotherapeutics Expands Management Team to Strengthen Financial Operations and Accelerate Clinical DevelopmentPress Release